This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Accenture announced it has made a strategic investment, through Accenture Ventures , in QuantHealth , an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients. Petra Jantzer, Ph.D.,
In our interview, Gil emphasizes the critical role of AI in expediting the discovery of new drugs, citing the lengthy and costly nature of traditional drugdevelopment processes. However, with AI-driven approaches, Aion Labs is paving the way for a paradigm shift in drug discovery.
The FDA issued a series of four patient-focused drugdevelopment (PFDD) guidance documents which outline how patient co-design needs to successfully happen. After all of this time and energy expended, it’s only right that patients would be witness to accountability of pharma/biotech to incorporate our collective voice.
Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. The same definition of patient engagement applies to industry, except that the interventions lead to more human centered design and value-based care.
Furthermore, by fostering connectivity and automating tasks, DHTs reduce administrative burdens, accelerate recruitment, and improve overall trial transparency, ultimately contributing to faster and more reliable drugdevelopment.
QuantHealth bridges these gaps by simulating trials at scale, to expedite, derisk, and optimize drugdevelopment. QuantHealth proudly supports several large pharma companies, numerous biotechs, as well as CROs, and other industry partners.
This ML-driven adaptive process can significantly accelerate the clinical drugdevelopment process and increase certainty along the way, resulting in more efficient, targeted, and ultimately more successful clinical trials. bringing new needed treatments to patients.”
About Koneksa Koneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical research and guide decision-making in drugdevelopment and market strategy. These adverse events often lead to hospitalizations and treatment interruptions that can reduce treatment efficacy.
As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drugdevelopment. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drugdevelopment.
Now, they have new tools such as artificial intelligence (AI) and machine learning (ML) that they can leverage to automatically scour medical literature for information to assist signal evaluation and medical review, or real-world-evidence insights that can lead to drug-safety improvements. Dave Latshaw, CEO at BioPhy 1.
We’re on a mission to revolutionize drugdevelopment in clinical trials by harnessing the power of our digital solutions with real-time, data-driven insights. The utilization of evidence-based digital biomarkers is the key to transforming healthcare,” said Chris Benko, CEO, Koneksa. “We’re
With the additional funding, Protai will expand its activities to include an oncology drug discovery pipeline, initially focusing on targets with a clearly-defined novel patient population biomarker, derived from its AI proteomics platform. In addition, Protai is supported by leading oncology experts, including Prof.
These individuals have personally built leading technology platforms supercharging drugdevelopment globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Jane Rhodes, Ph.D.,
Indivi is dedicated to unlocking the immense potential of digital biomarkers in drugdevelopment and healthcare by creating a unique symbiotic intersection between expert knowledge in Data Science, Clinical Science and Advanced Analytics (including machine learning and artificial intelligence).
23andMe tried to monetize its extensive genetic database by collaborating with pharmaceutical companies for drug research. While promising, drugdevelopment requires significant time and investment, delaying any financial returns and impacting the company’s short-term revenue.
For a person like me, who is impacted by a rare, neurological, and incurable disease, it’s my mission to ensure that patients’ perspectives are represented early and throughout drugdevelopment. We plan to gather these stakeholders at the upcoming Huntington Study Group conference this November 3-5 in Tampa, FL, to develop next steps.
Founded in 2018 and supported from the outset by LallianSe, the life sciences integrator, BrainTale has developed and commercializes an accessible, reliable and clinically validated brain measurement digital platform solution for drugdevelopers and physicians – neurologists, neuroradiologists and intensivists.
As a leader in patient advocacy, I am often asked to speak on the topic of patient centricity and patient advocacy from the biotech/pharma perspective. Meaningfully incorporating this insight in all areas of our work must be the cornerstone of participatory medicine for drugdevelopment and access. Did you enjoy this post?
–(BUSINESS WIRE)– Aviceda Therapeutics , a clinical-stage biotech company focused on developing next-generation immuno-modulators to treat diseases such as cancer, today announced a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (Queen’s). CAMBRIDGE, Mass.–(BUSINESS
Drawing on AstraZeneca’s deep experience of developing novel therapeutics and with insights from thousands of patients and clinical researchers, Evinova will provide established technology solutions to pharma, biotech and CROs to support clinical research globally.
About Automera Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation. Since our inception in 2022, ClavystBio has committed over US$220m to biotech, diagnostics, and digital health companies, as well as early-stage VC funds.
Their expertise in company building, capital formation, and drugdevelopment will be a tremendous resource to Avilar as the innovation leader in the new field of extracellular protein degradation.” For more information, please visit www.rac a p.com. About Sanofi Ventures Sanofi Ventures is the corporate venture capital arm of Sanofi.
Both Wellington and Forbion are visionaries and highly experienced biotech investors, and we look forward to working closely with them in our efforts to transform the gene editing landscape.” “Our billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drugdevelopment.
Existing investors include biotech giant Celgene Corp. , But key facets of its business didn’t develop as planned, say people familiar with the company. It had hoped to sell analytics to pharmaceutical companies as they increasingly incorporated genetic sequencing into drugdevelopment, these people say.
We aim to bring together relevant stakeholders, including payers, providers, patients groups, and biotech and when and where needed we cooperate with pharma, to be the one voice of the industry. The pipeline for new antibiotics is limited, which is partly due to how new drugdevelopment is funded.
SolasCure: This UK-based biotech company raised £15 million to develop a wound cleaning product based on an enzyme cloned from medical maggots. Pixacare: This French startup raised €3 million to automate wound care monitoring using AI-powered technology.
Already, this real-world, distributed time of diagnosis approach, has been used to cut down more than four years of estimated drugdevelopment timeline in the instance of PRAX-222, a new therapy for SCN2A, a rare genetic disorder of pediatric epilepsy.
The new year will bear witness to great innovation in biotech in the precision oncology space. In 2023, we will see more pharma companies integrating precision medicine programs with drugdevelopment programs, as well as increasing regulation on precision medicine solutions and/or tools that are combining machine learning and AI.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content